JP2020535151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535151A5 JP2020535151A5 JP2020517143A JP2020517143A JP2020535151A5 JP 2020535151 A5 JP2020535151 A5 JP 2020535151A5 JP 2020517143 A JP2020517143 A JP 2020517143A JP 2020517143 A JP2020517143 A JP 2020517143A JP 2020535151 A5 JP2020535151 A5 JP 2020535151A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192999.5 | 2017-09-25 | ||
| EP17192999 | 2017-09-25 | ||
| EP17203370 | 2017-11-23 | ||
| EP17203370.6 | 2017-11-23 | ||
| PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020535151A JP2020535151A (ja) | 2020-12-03 |
| JP2020535151A5 true JP2020535151A5 (https=) | 2022-03-24 |
| JPWO2019057992A5 JPWO2019057992A5 (https=) | 2022-03-24 |
| JP7461875B2 JP7461875B2 (ja) | 2024-04-04 |
Family
ID=63722372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517143A Active JP7461875B2 (ja) | 2017-09-25 | 2018-09-25 | 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220227854A1 (https=) |
| EP (5) | EP3687567B1 (https=) |
| JP (1) | JP7461875B2 (https=) |
| KR (2) | KR20250004928A (https=) |
| CN (2) | CN119215164A (https=) |
| AU (2) | AU2018335438B2 (https=) |
| BR (1) | BR112020005450A2 (https=) |
| CA (1) | CA3076691A1 (https=) |
| DK (1) | DK3687567T3 (https=) |
| ES (1) | ES3001197T3 (https=) |
| FI (1) | FI3687567T3 (https=) |
| HR (1) | HRP20241795T1 (https=) |
| HU (1) | HUE069945T2 (https=) |
| IL (1) | IL273533A (https=) |
| LT (1) | LT3687567T (https=) |
| MX (1) | MX2020003538A (https=) |
| MY (1) | MY204700A (https=) |
| PL (1) | PL3687567T3 (https=) |
| RS (1) | RS66415B1 (https=) |
| SG (1) | SG11202002258WA (https=) |
| SI (1) | SI3687567T1 (https=) |
| WO (1) | WO2019057992A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022002856A2 (pt) | 2019-08-30 | 2022-08-09 | 4TEEN4 Pharmaceuticals GmbH | Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CA3168978A1 (en) * | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20210285949A1 (en) * | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心（有限合伙） | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
| KR20250040987A (ko) * | 2022-07-20 | 2025-03-25 | 상하이 제유 파마슈티칼 컴퍼니 리미티드 | 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용 |
| WO2025152915A1 (zh) * | 2024-01-16 | 2025-07-24 | 上海济煜医药科技有限公司 | 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| ES2751549T3 (es) * | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| AU2010332932B2 (en) | 2009-12-14 | 2013-01-17 | Navigo Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RU2569745C2 (ru) | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| SG11201402362VA (en) * | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| DK2780717T3 (en) * | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| PL2594588T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| EP4086283A1 (en) * | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| EP2976646B1 (en) | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| KR20240033285A (ko) * | 2016-12-16 | 2024-03-12 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
-
2018
- 2018-09-25 FI FIEP18781997.4T patent/FI3687567T3/fi active
- 2018-09-25 PL PL18781997.4T patent/PL3687567T3/pl unknown
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
- 2018-09-25 SI SI201831189T patent/SI3687567T1/sl unknown
- 2018-09-25 EP EP18781997.4A patent/EP3687567B1/en active Active
- 2018-09-25 EP EP24205659.6A patent/EP4488295A3/en active Pending
- 2018-09-25 RS RS20241461A patent/RS66415B1/sr unknown
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 CN CN202411206189.XA patent/CN119215164A/zh active Pending
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 CN CN201880062062.1A patent/CN111511390B/zh active Active
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en not_active Ceased
- 2018-09-25 ES ES18781997T patent/ES3001197T3/es active Active
- 2018-09-25 HR HRP20241795TT patent/HRP20241795T1/hr unknown
- 2018-09-25 LT LTEPPCT/EP2018/075987T patent/LT3687567T/lt unknown
- 2018-09-25 HU HUE18781997A patent/HUE069945T2/hu unknown
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 AU AU2018335438A patent/AU2018335438B2/en active Active
- 2018-09-25 KR KR1020247040657A patent/KR20250004928A/ko active Pending
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 MY MYPI2020001569A patent/MY204700A/en unknown
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Ceased
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 DK DK18781997.4T patent/DK3687567T3/da active
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending